The company, CaaMTech, received an initial patent supporting the research in 2021. An article published Wednesday on the Greenstate site explains that the company is “developing pharmaceutical drugs for mental illnesses such as depression and mental disorders. obsessive-compulsive” and that she is “currently studying the therapeutic value of psilocybin in combination with cannabinoids”.
“Through its research, CaaMTech has isolated derivatives of psilocybin, cannabinoids, and terpenes,” says Greenstate.
Activate psychedelics and cannabinoids
Andrew Chadeayne, Founder and CEO of CaaMTech, said that “From day one, the company’s goal has been to integrate CaaMTech’s scientific innovation as much as possible into its intellectual property portfolio, as we develop the next generation of psychedelic drugs”.
“The acceptance of our first patent application gave a boost to the team that has worked steadily over the past four years to bring it to the finish line,” said Mr. Chadeayne in the ad. “While there are still hundreds of applications to process, this is an excellent start. »
“Strong patent protection and basic research give our drugs the fundamental support they need to pass clinical trials and become FDA-approved drugs,” he added.
“Compositions and methods comprising a psilocybin derivative” covers (among other things) the synergistic modulating effects of cannabinoids on serotonin receptor activation when administered in conjunction with a serotonin agonist. In simpler terms, CaaMTech has demonstrated that cannabinoids work synergistically with psychedelic tryptamines to produce their effects. In doing so, CaaMTech demonstrated the potential of two drugs once declared by the US federal government to have “no known medical value” to treat some of the world’s toughest mental health conditions.
The announcement states that “the notice of authorization [de l’Office américain des brevets et des marques (USPTO)] is a watershed moment for CaaMTech’s Intellectual Property Division, which has filed more than 100 additional patent applications since filing in 2017.”
“Authorization is the final hurdle of examination before a patent is granted,” the statement said.
Since the approval of this patent in 2021, Greenstate reports that “CaaMTech has shared results related to 4-PrO-DMT as a new synthetic alternative to psilocybin, among other things. »
“Distinct efforts can complement this work, such as SABI Mind’s research survey covering a myriad of topics, such as general acceptance or disregard for synthetic alternatives to compounds such as psilocybin. These measures, along with policy work, create broader pathways for patients seeking trustworthy, science-based psychedelic therapies,” the outlet reported.
Developing a treatment won’t be easy because of “serious hurdles to creating a combination compound.”
“Cannabinoids and psychedelics act on different receptors in the brain. Cannabinoids such as THC primarily bind to the CB1 cannabinoid receptor; CBC primarily binds to the CB2 receptor. Psychedelics like psilocybin primarily bind to serotonin 5-HT2A receptors,” the journal states.
“But research has shown that the cannabinoid CBD can bind to serotonin, and when serotonin is paired with a cannabinoid CB2 receptor, the combination of the two can do things that neither receptor can do alone… Scope by the potential of the combined compound, the medical cannabis community is increasingly enthusiastic. For example, cannabis combined with psychedelics has been found to significantly shrink tumors in breast cancer.”
CaaMTech, based in Issaquah, Wash., bills itself as “the premier drug discovery and lead optimization company focused on developing psychedelic drugs that meet the standards of modern medicine.”